Subscribe
JarTee / Shutterstock.com
18 July 2025NewsEuropeMuireann Bolger

AbbVie blocks Humira antitrust suit

Non-profit alleges that Humira pricing displaced essential healthcare, violated EU competition law and breached human rights | Court notes ‘social significance’ of case—but this can’t translate into ‘legal standing’.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AbbVie accused of delay tactics in $1.3bn Humira dispute
16 November 2023   Big pharma company relies on procedural arguments to fend off a complaint alleging that it engaged in excessive pricing | Feud centres on one of the most successful blockbuster drugs of all time.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.
Biotechnology
The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn
9 March 2023   The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.


Editor's picks

In-house with Bayer: ‘Focus on quality early and stay close to inventors’
Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025

Editor's picks

Europe
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
15 July 2025
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025

More on this story

Big Pharma
AbbVie accused of delay tactics in $1.3bn Humira dispute
16 November 2023   Big pharma company relies on procedural arguments to fend off a complaint alleging that it engaged in excessive pricing | Feud centres on one of the most successful blockbuster drugs of all time.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.
Biotechnology
The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn
9 March 2023   The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.

More on this story

Big Pharma
AbbVie accused of delay tactics in $1.3bn Humira dispute
16 November 2023   Big pharma company relies on procedural arguments to fend off a complaint alleging that it engaged in excessive pricing | Feud centres on one of the most successful blockbuster drugs of all time.
Big Pharma
Humira: lessons from 20 years of patents, pricing and profits
21 March 2023   As AbbVie’s multibillion-dollar blockbuster drops over the patent cliff, is it time to tighten up patent and pricing strategies in the US? Sarah Speight investigates.
Biotechnology
The Dutch non-profit taking on AbbVie for ‘overpricing' Humira by $1.3bn
9 March 2023   The Pharmaceutical Accountability Foundation has accused the pharma giant of excessively pricing its blockbuster drug, and believes it could influence the regulation of pricing and patent policy for global medicines in the process.

More features

WATCH: Enabling success—mastering s112 in the new era of life sciences patents
AstraZeneca suffers defeat over $7bn diabetes patent
US firm Brownstein nabs five from Crowell ‘at pivotal moment’
American Regent secures rare PI win in Hatch-Waxman dispute
WATCH: Patents s101—how to overcome the current complexity of patent eligibility in the US
In-house with Bayer: ‘Focus on quality early and stay close to inventors’
J&J sues over schizophrenia drug generic following patent victory
WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era